ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ILMN Stock Price » ILMN Stock News

Illumina Share News

 Illumina (mm) Stock Price
ILMN Stock Price
 Illumina (mm) Stock Chart
ILMN Stock Chart
 Illumina (mm) Stock News
ILMN Stock News
 Illumina (mm) Company Information
ILMN Company Information
 Illumina (mm) Stock Trades
ILMN Stock Trades

Roche Expected To Extend Hostile Illumina Bid On Unchanged Terms

-- Offer period expires Friday at 1800 EDT, or 2200 GMT -- Roche may increase offer eventually, but will bide its time, say analysts -- Roche may still decided to walk away from deal By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Roche Holding AG (ROG.VX) is expected Friday to extend for the second time its unsolicited offer to buy U.S. gene-sequencing company Illumina Inc.(ILMN) without increasing its bid, as the Swiss drug maker carries on with its waiting strategy. Roche, which is bidding $44.50 a share for the San Diego-based company, last month already extended its $5.7 billion cash bid offer until Friday, 1800 EDT. Analysts believe the Basel-based pharmaceutical giant will stick to its waiting approach, and reiterate that the offer on the table is "full and fair," even as it has met fierce resistance from Illumina's board, which dismissed it as too low. Roche wasn't immediately available to comment. Earlier this week, Roche appealed directly to Illumina's shareholders, urging them to tender their shares and vote for Roche's director nominees at Illumina's upcoming annual meeting on April 18. "Roche is expected to raise the bid by about 20% eventually, but for now, they will maintain the pressure and try to talk to Illumina's majority investors to bring them on their side," said David Kaegi, analyst at private bank Sarasin in Zurich. "This will take some more time, and the whole process will likely drag on over the summer," he added. Kaegi said that Roche will probably not be successful with their director nominees and that Illumina's shareholders will proceed to elect the candidates proposed by the board at their upcoming AGM in April. The company has written to its own shareholders urging them to reject Roche's "unsolicited and opportunistic efforts to acquire Illumina on grossly inadequate terms." Illumina's icy stance might be understandable given that the company's stock as recently as last summer traded in the region of $70 a share. However, Roche's offer of $44.50 per share still represents a premium of more than 60% over Illumina's stock price mid-December before rumors of the potential transaction first surfaced. Illumina closed at $25.96 on December 13, 2011. "Illumina is expensive. If Roche walks away, the stock would come down again," said Birgit Kulhoff, a fund manager with private bank Rahn & Bodmer in Zurich. Kulhoff said Roche would only be prepared to offer a "small increase" over the existing price, before calling off the deal. "There are alternatives, not necessarily better ones, but still alternatives," she said. Roche, which launched the bid last January, wants to buy Illumina to underpin its personalized medicines startegy. The world's largest maker of cancer drugs has a history of success with hostile acquisitions and faces little risk that rival bidders will jump into the fray to acquire Illumina. Earlier buys, such as that of diagnostic test-maker Ventana or U.S. biotech group Genentech, indicate that Roche is content to bide its time with deals. At 0935 GMT, Roche shares were down 0.5% at CHF157.80. Illumina shares closed at $50.22 Thursday. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stock News for Illumina (ILMN)
02/21/201713:21:21Current Report Filing (8-k)
02/21/201706:30:00Illumina to Webcast Live Presentation at the Cowen and Company...
02/20/201709:00:00Illumina Names John W. Thompson to Its Board of Directors, Bringing...
02/14/201710:54:35Statement of Ownership (sc 13g)
02/14/201706:10:26Annual Report (10-k)
02/13/201717:26:21Amended Statement of Ownership (sc 13g/a)
02/13/201708:33:01Current Report Filing (8-k)
02/10/201715:57:00Statement of Changes in Beneficial Ownership (4)
02/10/201715:34:03Amended Statement of Ownership (sc 13g/a)
01/31/201716:32:30Current Report Filing (8-k)
01/31/201716:05:00Illumina Reports Full Financial Results for Fourth Quarter and...
01/30/201703:00:00Illumina Debuts VeriSeq™ Analysis Software (48 Samples), Optimized D...
01/30/201703:00:00Illumina lance le logiciel d'analyse VeriSeq™ (48 échantillons), av...
01/30/201703:00:00Illumina präsentiert Analysesoftware VeriSeq™ (48 Proben), op...
01/27/201716:36:43Current Report Filing (8-k)
01/27/201710:39:32Amended Statement of Ownership (sc 13g/a)
01/27/201709:00:00Illumina Names Caroline Dorsa to Its Board of Directors, Adding...
01/25/201714:50:18Amended Statement of Ownership (sc 13g/a)
01/24/201716:01:00CareDx to acquire SBT Resolver™ HLA Typing Products from Illumina
01/19/201717:57:23Statement of Changes in Beneficial Ownership (4)

Illumina and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations